January 31, 2018 / 1:42 PM / 6 months ago

BRIEF-Dermira Initiates Mid-Stage Study Testing Eczema Treatment

Jan 31 (Reuters) - Dermira Inc:

* DERMIRA INITIATES PHASE 2B DOSE-RANGING STUDY EVALUATING LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

* DERMIRA INC - ‍TOPLINE RESULTS FROM PHASE 2B DOSE-RANGING STUDY​ EXPECTED IN FIRST HALF OF 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below